The Floor a Buyer Would Set — Elastic Through an Acquirer's Eyes
The Floor a Buyer Would Set — Elastic Through an Acquirer's Eyes
Every prior chapter has valued Elastic the way the public market does: a multiple on revenue, a yield on cash, a scenario on growth. Chapter 6 showed the stock at roughly 3x revenue already embeds the bear — the steady-compounder outcome — leaving the Search-AI re-acceleration case nearly unpriced, with the downside "cushioned by net cash." Chapter 8 quantified that cushion at the cash line: about \$0.8B of net cash, ~\$7.60 a share. This chapter tests the same downside from the one angle the report has not used — the private market. What would a strategic or financial buyer pay for this business, and does that number put a floor under the stock meaningfully above the net-cash line?
The answer is a paradox an investor has to hold in both hands. By the multiples the private market has actually paid for slowing-but-cash-generative infrastructure software, Elastic is worth far more than 3x revenue — a take-out in the \$80–\$120 range, 40% to 110% above the ~\$57 quote. But Elastic is a Dutch N.V. wrapped in a foundation-based poison pill, ~80% owned by insiders, and its headline cash flow is paid for in stock. The replacement value is real; the path to collecting it is gated shut. The floor exists — you just can't stand on it.
What the public market pays vs. what the private market has paid
Start with the gap. Elastic's enterprise value is about \$5.3B against \$1.74B of FY2026 revenue [1] — 3.0x trailing sales. That is roughly where the public market values a 17%-grower with a thin GAAP profit. The private market, over the last cycle, has not valued comparable franchises anywhere near that low.
Sources: deal announcements — Cisco–Splunk (\$28B, ~\$4B ARR acquired, all-cash at \$157/share), Francisco Partners/TPG–New Relic (\$6.5B, \$87/share all-cash), Francisco Partners–Sumo Logic (\$1.7B); Elastic enterprise value and revenue from Q4 FY2026 results [2].
These are not stretched comparisons. Splunk — Elastic's closest peer in log analytics and SIEM, named as such in the bull case for client migration — went to Cisco for \$28B all-cash, roughly 7x its revenue, against a business growing in the mid-teens. New Relic and Sumo Logic are observability companies, the same arena where Elastic competes with Datadog and Dynatrace, and both were taken private at ~5–6.5x revenue precisely because they threw off cash and traded cheaply on the public tape. Elastic today is a better business than Sumo Logic was — larger, faster-growing, FCF-positive, net cash — and trades at little more than half its take-out multiple.
What those multiples imply for Elastic's price
Apply that precedent band to Elastic's own revenue and balance sheet. Holding FY2026 revenue of \$1.74B and net cash of ~\$0.8B fixed, each turn of EV/revenue maps to a per-share value:
Source: derived from FY2026 revenue (\$1.74B) and ~\$0.8B reported net cash, divided by 107.2M diluted shares [3]; precedent multiples from infrastructure-software deal announcements.
The shares last traded near \$57. The current public multiple of 3.0x reproduces almost exactly that price — confirming the chapter-6 finding that the tape prices the bear. But the lowest precedent in the table, Sumo Logic's ~5x, implies roughly \$90; the observability take-privates at 5.5–6.5x imply \$97–\$113; a Splunk-style strategic premium implies \$121. Even a deliberately conservative 4.5x — below every deal cited — lands at \$80, a 40% premium. The replacement value of Elastic's installed base, judged by what acquirers have actually paid for slower, smaller versions of the same thing, sits well north of where the stock trades. That is the private-market floor the report has been circling: not the ~\$7.60 of net cash, but something closer to \$80 before any control premium.
Current EV / Revenue
Implied at 4.5x (conservative floor)
Implied at 6.5x (New Relic comp)
Sources: current multiple per Q4 FY2026 results [4]; implied prices derived as above, shown at the 4.5x and 6.5x take-out multiples.
Why the floor is gated: a Dutch poison pill that has never been drawn
Here is where the private-market case meets the wall that makes Elastic different from a Delaware software company. Elastic is incorporated in the Netherlands, and at its 2018 IPO it built one of the most complete takeover defenses available under Dutch law. The board was authorized to issue preference shares — or rights to subscribe for them — up to 100% of the issued share capital to a separate, newly incorporated foundation (a stichting) structured to operate independently of the company [5]. The foundation holds a call option, in principle for an indefinite period, that lets it acquire enough preference shares to match the ordinary shares held by everyone else — and it can exercise repeatedly. Its stated purpose is blunt: to "prevent, delay or otherwise complicate an unsolicited takeover bid" and to "resist unwanted influence" from shareholders [6].
This is not boilerplate that lapsed. The FY2026 10-K confirms the machinery is still loaded and still untriggered: "As of April 30, 2026, there were no preference shares issued or outstanding," and preference shares "may currently be issued" under standing authority renewed annually [7]. A foundation that can flood the register with friendly preference shares is a poison pill with no expiry — it makes a hostile tender effectively impossible, because any unwanted bidder can be diluted at will.
The pill does not stand alone. The articles also stack a staggered three-year board, binding board nominations that shareholders can override only with a two-thirds majority representing at least half the issued capital, and a rule that amendments to the articles reach a vote only on the board's own proposal [8]. On top of the legal architecture sits ownership: executives, directors and 5%-plus holders control a large block — a concentration the company itself warns "might also have the effect of delaying or preventing a change of control" [9]. Founder Shay Banon and early backers, as Chapter 5 detailed, sit near the top of that register.
The practical consequence: the \$80-plus private-market value is real, but it is only collectible if Elastic's own board and founders decide to sell. An activist cannot accumulate a stake and force an auction. A strategic cannot launch a hostile bid. There is no path to the floor that does not run through a willing seller — and the people who would have to be willing are insiders with a 14.8%-to-21% stake each and a founder-CTO who has never signaled an exit. The takeover defense converts the private-market floor from a catalyst you can underwrite into a tail option you can only hope for.
The catch even a friendly buyer hits: the cash isn't all there
Suppose the board did invite a buyer. The precedent multiples assume the acquirer is paying for the cash flow Elastic reports. But Chapter 4 established that Elastic's ~18–20% free-cash-flow margin is, on an owner basis, mostly an artifact of stock-based compensation — roughly 85 cents of every reported FCF dollar is consumed once you charge the comp the company pays in shares rather than cash. That wedge changes who can buy, and at what price.
A private-equity buyer is the cleanest structural fit — Elastic is a textbook LBO candidate: Rule-of-40 at 37%, net cash, cheap on the tape, the exact profile Francisco Partners bought twice in observability. But a take-private firm cannot sterilize compensation the way the public company does, by buying back stock against a liquid market (the maneuver Chapter 4 showed Elastic using to mop up dilution). In private hands the engineers still have to be paid, and increasingly in cash — which means the ~\$300M of annual SBC migrates onto the real P&L and the headline FCF an LBO model would underwrite shrinks toward the thin owner-FCF number. The owner-economics problem that discounts the public stock discounts the private bid too.
A strategic buyer escapes the comp math but faces a thinner field than the precedents suggest. The natural acquirers of a search-and-machine-data platform are the hyperscalers and the security/observability consolidators — and most have already chosen build or fork over buy. AWS forked Elasticsearch into OpenSearch rather than acquire (Chapter 2); Microsoft, Google and Oracle run their own search and vector stacks; Cisco already spent its \$28B on Splunk and is unlikely to buy a second machine-data platform; Datadog, CrowdStrike and Palo Alto compete with Elastic head-on and have little reason to pay a premium for a sub-scale rival. The deepest-pocketed logical buyers are the same names that decided years ago they did not need to own this asset. That does not void the precedent multiples — a motivated strategic would pay them — but it thins the queue of bidders who would ever knock.
One final friction: any change of control triggers a put on the \$575M 4.125% Senior Notes at 101% of principal [10] — a modest, not prohibitive, cost a buyer must fund on day one, but one more line in the deal model.
What this adds to the thesis
The through-line asks whether the market is right to price Elastic as a steady ~3x-revenue compounder. The acquirer's-eye lens sharpens both halves of the answer. It reinforces the chapter-6 asymmetry: the downside is cushioned by more than net cash, because the replacement value of this installed base — judged by what Cisco, Francisco Partners and TPG actually paid for slower, smaller versions of the same franchise — sits near \$80 a share, roughly 40% above the quote, before any control premium. The 3x public multiple is a genuine discount to private-market worth.
But it complicates the idea that the discount is a coiled spring. The mechanism that would close the gap — a takeover — is the one outcome Elastic's structure is engineered to prevent. The poison-pill foundation, the staggered board, the binding nominations and the insider block mean the private-market floor is unarbitrageable: no buyer can reach it without the founders' blessing, and nothing in the record says that blessing is coming. The owner-economics wedge from Chapter 4 then trims what even a willing buyer would pay.
So the take-out floor belongs in the investment case the way a fire exit belongs in a building: reassuring that it exists, not something you plan to use. A value investor cannot underwrite Elastic on the expectation of a bid — the structure forecloses it. You are left underwriting the standalone compounding case — as the closing verdict will frame it in Chapter 7 — with the private-market premium as an unbankable tail. The floor is high. The door to it is locked from the inside.
Bottom line: precedent infrastructure-software take-outs (Splunk ~7x, New Relic ~6.5x, Sumo Logic ~5x revenue) imply an Elastic worth of roughly \$80–\$120 a share versus the ~\$57 quote — a real private-market floor well above net cash. But Elastic's Dutch foundation poison pill, staggered board, binding nominations and ~80% insider control make that floor collectible only if the board and founders choose to sell, and the SBC wedge trims what even a friendly buyer could underwrite. The floor reinforces the downside cushion; it is not a catalyst.